1. Home
  2. AYTU vs SPRC Comparison

AYTU vs SPRC Comparison

Compare AYTU & SPRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • SPRC
  • Stock Information
  • Founded
  • AYTU N/A
  • SPRC 2004
  • Country
  • AYTU United States
  • SPRC Israel
  • Employees
  • AYTU N/A
  • SPRC N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • SPRC Biotechnology: Pharmaceutical Preparations
  • Sector
  • AYTU Health Care
  • SPRC Health Care
  • Exchange
  • AYTU Nasdaq
  • SPRC Nasdaq
  • Market Cap
  • AYTU 10.5M
  • SPRC 11.6M
  • IPO Year
  • AYTU N/A
  • SPRC N/A
  • Fundamental
  • Price
  • AYTU $1.72
  • SPRC $0.58
  • Analyst Decision
  • AYTU
  • SPRC
  • Analyst Count
  • AYTU 0
  • SPRC 0
  • Target Price
  • AYTU N/A
  • SPRC N/A
  • AVG Volume (30 Days)
  • AYTU 27.9K
  • SPRC 24.6M
  • Earning Date
  • AYTU 02-12-2025
  • SPRC 02-15-2025
  • Dividend Yield
  • AYTU N/A
  • SPRC N/A
  • EPS Growth
  • AYTU N/A
  • SPRC N/A
  • EPS
  • AYTU N/A
  • SPRC N/A
  • Revenue
  • AYTU $79,759,000.00
  • SPRC $1,747,000.00
  • Revenue This Year
  • AYTU N/A
  • SPRC N/A
  • Revenue Next Year
  • AYTU N/A
  • SPRC N/A
  • P/E Ratio
  • AYTU N/A
  • SPRC N/A
  • Revenue Growth
  • AYTU N/A
  • SPRC N/A
  • 52 Week Low
  • AYTU $1.30
  • SPRC $0.20
  • 52 Week High
  • AYTU $3.45
  • SPRC $6.78
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 54.22
  • SPRC 51.76
  • Support Level
  • AYTU $1.68
  • SPRC $0.49
  • Resistance Level
  • AYTU $1.93
  • SPRC $0.91
  • Average True Range (ATR)
  • AYTU 0.12
  • SPRC 0.22
  • MACD
  • AYTU 0.00
  • SPRC -0.03
  • Stochastic Oscillator
  • AYTU 36.36
  • SPRC 15.82

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About SPRC SciSparc Ltd.

SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

Share on Social Networks: